Parathyroid Hormone (pth) Or Derivative Patents (Class 514/11.8)
  • Patent number: 11116816
    Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: September 14, 2021
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Patent number: 10996208
    Abstract: Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: May 4, 2021
    Assignee: Radius Health, Inc.
    Inventors: Greg Williams, Naveen Palwai, David Hanley
  • Patent number: 10993879
    Abstract: The present invention relates to a pharmaceutical formulation powder that contains 17?-hydroxyprogesterone caproate (17-OHPC) powder and the method of producing the formulation produces particles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-OHPC as taught herein may be used to reduce cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and involve the inhibition of p38 mitogen activating protein kinase (MAPK) activity. The 17-OHPC powder formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) and/or fluticasone with 17-OPHC.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 4, 2021
    Assignee: SHENZHEN EVERGREEN THERAPEUTICS CO., LTD.
    Inventors: Chang Lee, Tao Tom Du
  • Patent number: 10980862
    Abstract: Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: April 20, 2021
    Assignees: Radius Health, Inc., Kindeva Drug Delivery L.P.
    Inventors: Gary Hattersley, Alan Harris, Jamal Saeh, Ehab Hamed, Kenneth Brown, Daniel Dohmeier, Joan Moseman, Ying Zhang, Lisa Dick
  • Patent number: 10603361
    Abstract: Disclosed herein are methods for treating a subject with an alkaline phosphatase deficiency, further comprising monitoring additional anaiytes, e.g., calcium, parathyroid hormone and/or vitamin D, with treatment modifications as indicated by the levels, e.g., serum levels, of the additional anaiytes.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: March 31, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventor: Tatjana Odrljin
  • Patent number: 10568937
    Abstract: Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 25, 2020
    Assignees: Radius Health, Inc., 3M Innovative Properties Company
    Inventors: Gary Hattersley, Alan Harris, Jamal Saeh, Ehab Hamed, Kenneth Brown, Daniel Dohmeier, Joan Moseman, Ying Zhang, Lisa Dick
  • Patent number: 10519213
    Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: December 31, 2019
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, OCHSNER CLINIC FOUNDATION, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY
    Inventors: Robert C. Gensure, Joshua Sakon, Osamu Matsushita, Tulasi Ponnapakkam
  • Patent number: 10406202
    Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: September 10, 2019
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Patent number: 10358471
    Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: July 23, 2019
    Assignees: The Board of Trustees of the University of Arkansas, Ochsner Clinic Foundation, National University Corporation Kagawa university
    Inventors: Robert C. Gensure, Joshua Sakon, Osamu Matsushita, Tulasi Ponnapakkam
  • Patent number: 10202434
    Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: February 12, 2019
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, OCHSNER CLINIC FOUNDATION, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY
    Inventors: Robert C. Gensure, Joshua Sakon, Osamu Matsushita, Tulasi Ponnapakkam
  • Patent number: 10047343
    Abstract: The present disclosure provides methods of producing cartilage in vitro. The present disclosure provides treatment methods, involving introducing in vitro-produced cartilage into a treatment site in vivo. The present disclosure provides methods of enhancing bone formation, the method involving introducing in vitro-produced hypertrophic cartilage into a treatment site in vivo.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: August 14, 2018
    Inventor: Alfred Kuo
  • Patent number: 9968660
    Abstract: The present invention provides a means effective for bone regeneration or bone augmentation. Provided is a method of bone regeneration or bone augmentation, comprising: implanting a porous composite at a site in need of the bone regeneration or bone augmentation, and administering parathyroid hormone (PTH) to a subject in need of the bone regeneration or bone augmentation, wherein the porous composite comprises calcium phosphate.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: May 15, 2018
    Assignee: TOYOBO CO., LTD.
    Inventors: Shinji Kamakura, Satoru Nakajou, Atsushi Iwai, Fumihiko Kajii, Hidenori Tanaka
  • Patent number: 9962135
    Abstract: Disclosed herein is a trabecular bone analyzer that can quantitatively determine the state of trabecular bone accurately. The trabecular bone analyzer of may perform trabecular bone analysis on a tomographic image D. In the tomographic image D, trabeculae forming a network may appear without overlapping. Therefore, such trabecular bone analysis may more accurately quantify trabecular bone.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: May 8, 2018
    Assignee: Shimadzu Corporation
    Inventor: Junya Yamamoto
  • Patent number: 9701712
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: July 11, 2017
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Patent number: 9700485
    Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, FORTEO® (recombinant human teriparatide), DULAGLUTIDE® (LY2189265), recombinant insulin glargine, RAMUCIRUMAB® (IMC-1121B), SOLANEZUMAB® (LY2062430), IXEKIZUMAB® (LY2439821), TABALUMAB® (LY2127399), NECITUMUMAB® (IMC-11F8), or CIXUTUMUMAB® (IMC-A12).
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: July 11, 2017
    Assignee: Corning Incorporated
    Inventors: Wendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
  • Patent number: 9622975
    Abstract: The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins. e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: April 18, 2017
    Assignee: Novartis AG
    Inventors: Moise Azria, Simon David Bateman, Anasuya Ashok Ghosh, Shoufeng Li, Alan Edward Royce
  • Patent number: 9492508
    Abstract: Disclosed are two PTH analog ligands, SP-PTH-AAK and Aib-SP-PTH-AAK, that have long-acting activity at the PTH receptor, as demonstrated both in vitro and in vivo. These polypeptides are thus particularly useful in the treatment of diseases, such as hypoparathyroidism, in which long-acting activity is desired. The method of making the analog polypeptides is also disclosed.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: November 15, 2016
    Assignees: The General Hospital Corporation, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Thomas J. Gardella, John T. Potts, Jr., Harald Jueppner, Makoto Okazaki
  • Patent number: 9272040
    Abstract: Pharmaceutical compositions for the effective oral delivery of a parathyroid hormone, PTH, as well as methods for administration of the compositions are provided. Additionally, methods for stimulating new bone formation and treating and/or preventing osteoporosis are also provided.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: March 1, 2016
    Assignee: Novartis AG
    Inventors: Moise Azria, Simon David Bateman
  • Patent number: 9062300
    Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: June 23, 2015
    Assignees: National University Corporation Kagawa University, Ochsner Clinic Foundation, The Board of Trustees of the University of Arkansas
    Inventors: Robert C. Gensure, Joshua Sakon, Osamu Matsushita, Tulasi Ponnapakkam
  • Publication number: 20150140059
    Abstract: This invention relates, e.g., to a synthetic compound, Oxy149, having the structure (Formula I) or a bioactive or pharmaceutical composition comprising Oxy149 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders. Oxy149 can be delivered either locally or systemically.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 21, 2015
    Inventors: Farhad Parhami, Michael Jung, Frank Stappenbeck, William Pierce, K. Grant Taylor, Kevyn E. Merten
  • Publication number: 20150141339
    Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.
    Type: Application
    Filed: October 21, 2014
    Publication date: May 21, 2015
    Inventors: Stephen Hodges, Robin Soper
  • Publication number: 20150132327
    Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    Type: Application
    Filed: January 21, 2015
    Publication date: May 14, 2015
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro OKANO, Muneyoshi MAKABE, Kouki OGAWA
  • Patent number: 8999932
    Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: April 7, 2015
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
  • Publication number: 20150093419
    Abstract: The invention provides a pharmaceutical composition comprising a mixture of (a) an active macromolecular principle, and (b) an aromatic alcohol absorption enhancer chosen from butylated hydroxy toluene, butylated hydroxy anisole and analogues and derivatives thereof, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than or equal to that of the active macromolecular principle, and further comprises a pharmaceutical composition comprising a mixture of (a) an active macromolecular principle, (b) an aromatic alcohol absorption enhancer chosen from propyl gallate, butylated hydroxy toluene, butylated hydroxy anisole and analogues and derivatives thereof, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than or equal to that of the active macromolecular principle, and (c) a solubilisation aid capable of increasing the solubility of the aromatic alcohol absorption enhancer in aqueous media.
    Type: Application
    Filed: December 4, 2014
    Publication date: April 2, 2015
    Inventor: ROGER R.C. NEW
  • Patent number: 8987200
    Abstract: The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 24, 2015
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Gregory Bell, Sarah Walter, Felix Karim
  • Patent number: 8987201
    Abstract: Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: March 24, 2015
    Assignee: Michigan Technological University
    Inventor: Seth W. Donahue
  • Publication number: 20150072019
    Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 12, 2015
    Inventors: Michaela Kneissel, Vito Gaugnano, Diana Graus Porta, Simon Wöhrle
  • Publication number: 20150044296
    Abstract: The present invention is directed to kit, drug combinations and methods for promoting endogenous bone marrow (BM)-derived vasculogenic progenitor cell (PC) mobilization, sensitization of such cells and chemotaxis to sites of joint injury or disease. One embodiment of the present invention, directed to a method of promoting joint complex healing, comprises the step of administering an effective amount of a bone marrow (BM) derived vasculogenic progenitor cell mobilization factor to an animal or human exhibiting joint injury or joint disease. The method further comprises the step of administering, concurrently to the mobilization factor, an effective amount of a progenitor cell sensitizing factor to mobilize progenitor cells and sensitize the progenitor cells to one or more chemotactic agents present at the site of joint injury or joint disease.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 12, 2015
    Inventors: Leonard B. MILLER, Stephen WARREN
  • Patent number: 8936804
    Abstract: This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: January 20, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Sheldon Suton Lin, David Naisby Paglia, James Patrick O'Connor, Eric Breitbart, Joseph Benevenia
  • Publication number: 20150011473
    Abstract: Stable pharmaceutical formulations comprising human parathyroid hormone are provided. The stabilized aqueous pharmaceutical formulation comprises human parathyroid hormone and a buffer selected from lactate or glutamate. In another embodiment a stabilized aqueous pharmaceutical formulation comprising human parathyroid hormone selected from the group of (1-34), (1-37), (1-38), (1-41), a buffer selected from lactate or glutamate, a stabilizing agent and a parenterally acceptable preservative, wherein the said formulation is sterile and ready for parenteral administration and having pH in the range of 3 to 7 is provided.
    Type: Application
    Filed: January 19, 2013
    Publication date: January 8, 2015
    Inventors: Vaibhav Dnyaneshwar Deokar, Anjali Deepak Apte-Deshpande, Sheetal Arvind Raut, Balaji Damodaran, Cyrus Karkaria
  • Publication number: 20140378382
    Abstract: Described are polypeptide analogs of parathyroid hormone (PTH) that include at least two non-adjacent ?-amino acid residues in place of a naturally occurring ?-amino acid residues. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.
    Type: Application
    Filed: June 23, 2014
    Publication date: December 25, 2014
    Applicant: Massachusetts General Hospital
    Inventors: Samuel H. Gellman, Ross W. Cheloha, Thomas J. Gardella
  • Publication number: 20140357560
    Abstract: [Object] To provide a method of treating osteoporosis by PTH that has excellent safety and high efficacy. To provide a method for inhibiting/preventing bone fractures by PTH that has excellent safety. And to provide a drug to do this. [Means of Achievement] A drug containing PTH as the active ingredient, characterized in that a unit dose of PTH of 100 to 200 units is administered weekly in the above method.
    Type: Application
    Filed: July 14, 2014
    Publication date: December 4, 2014
    Inventors: Shinichiro SHIRAE, Yasuo NAKAMURA, Yuiko OYA, Yoshihide NOZAKI, Nobuyuki KOBAYASHI, Tatsuhiko KURODA, Hiroki KATO, Masahi SERADA, Kazuyoshi HORI
  • Publication number: 20140341888
    Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, FORTEO® (recombinant human teriparatide), DULAGLUTIDE® (LY2189265), recombinant insulin glargine, RAMUCIRUMAB® (IMC-1121B), SOLANEZUMAB® (LY2062430), IXEKIZUMAB® (LY2439821), TABALUMAB® (LY2127399), NECITUMUMAB® (IMC-11F8), or CIXUTUMUMAB® (IMC-A12).
    Type: Application
    Filed: April 23, 2014
    Publication date: November 20, 2014
    Applicant: CORNING INCORPORATED
    Inventors: Wendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
  • Publication number: 20140335169
    Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
    Type: Application
    Filed: January 17, 2014
    Publication date: November 13, 2014
    Applicant: Enteris BioPharma, Inc.
    Inventors: William Stern, Angelo P. Consalvo
  • Publication number: 20140322292
    Abstract: Methods of promoting bone healing or regeneration by locally administering insulin mimetic agents to patients in need thereof and new uses of insulin-mimetic compounds for accelerating bone-healing processes are disclosed. Bone injury treatment and void filler devices, products and kit suitable for local administration of insulin-mimetic agents or compositions thereof to patients in need of such treatment are also disclosed.
    Type: Application
    Filed: November 29, 2012
    Publication date: October 30, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sheldon S. Lin, David N. Paglia, James P. O'Connor, Joseph Benevenia, Aaron Wey, Sangeeta Subramanian, John D. Koerner
  • Publication number: 20140315809
    Abstract: Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The methods described herein are also effective in slowing the progression of kidney disease and preserving kidney function. Compositions used in the described methods are also provided and comprise calcimimetics which function as agonists of the calcium sensing receptor (CaSR).
    Type: Application
    Filed: November 12, 2012
    Publication date: October 23, 2014
    Applicant: Kai Pharmaceuticals, Inc.
    Inventors: Sarah Walter, Gregory Bell, James E. Tomlinson
  • Publication number: 20140256632
    Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.
    Type: Application
    Filed: May 22, 2014
    Publication date: September 11, 2014
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: John Dietrich, Sverker Ljunghall, Sven Sjorgen
  • Publication number: 20140249084
    Abstract: [Object] To provide a method of treating osteoporosis by PTH that has excellent safety and high efficacy. To provide a method for inhibiting/preventing bone fractures by PTH that has excellent safety. And to provide a drug to do this. [Means of Achievement] A drug containing PTH as the active ingredient, characterized in that a unit dose of PTH of 100 to 200 units is administered weekly in the above method.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 4, 2014
    Applicant: ASAHI KASEI PHARMA CORPORATION
    Inventors: Shinichiro SHIRAE, Yasuo NAKAMURA, Yuiko OYA, Yoshihide NOZAKI, Nobuyuki KOBAYASHI, Tatsuhiko KURODA, Hiroki KATO, Masashi SERADA, Kazuyoshi HORI
  • Publication number: 20140248365
    Abstract: The present invention relates to teriparatide peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of disorders, e.g., of bone density. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprise at least one glutathione; and at least one teriparatide peptide that is non-covalently bound to the corona.
    Type: Application
    Filed: February 6, 2014
    Publication date: September 4, 2014
    Inventors: Thomas Rademacher, Phillip Williams
  • Publication number: 20140228293
    Abstract: The present invention provides parathyroid hormone and/or parathyroid hormone-related protein analogs, compositions thereof and methods thereto.
    Type: Application
    Filed: March 1, 2012
    Publication date: August 14, 2014
    Applicants: THE GENERAL HOSPITAL CORPORATION, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Samuel J. Danishefsky, Shiying Shang, Zhongping Tan, Suwei Dong, Jianfeng Li, Thomas Gardella
  • Patent number: 8802622
    Abstract: The invention provides a powdered composition for nasal administration, comprising a physiologically active peptide and cellulose acetate as the base, and having excellent nasal absorption for physiologically active peptides.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: August 12, 2014
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masaru Matsumoto, Shuji Takeda, Kyohei Nobori
  • Publication number: 20140212504
    Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
    Type: Application
    Filed: April 2, 2014
    Publication date: July 31, 2014
    Inventors: Jeffry G. WEERS, Thomas E. TARARA, Luis A. DELLAMARY, Jean G. RIESS, Ernest G. SCHUTT
  • Patent number: 8778403
    Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: July 15, 2014
    Assignee: Mannkind Corporation
    Inventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin
  • Patent number: 8765674
    Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: July 1, 2014
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: John Dietrich, Sverker Ljunghall, Sven Sjogren
  • Publication number: 20140171362
    Abstract: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: Xeris Pharmaceuticals, Inc.
    Inventors: Steven Prestrelski, John Kinzell
  • Patent number: 8748382
    Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: June 10, 2014
    Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.
    Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
  • Patent number: 8729019
    Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: May 20, 2014
    Assignee: Mannkind Corporation
    Inventors: Keith A. Oberg, Joseph Sulner
  • Patent number: 8722075
    Abstract: A method for promoting bone formation is provided. More specifically, a method for promoting bone formation by promoting osteoclast formation is provided. In one embodiment, an implant comprising an implantable material and an osteoclast stimulating substance is provided.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: May 13, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Lawrence A. Shimp, Keyvan Behnam, Guobao Wei, Abdulhafez A. Selim
  • Publication number: 20140088014
    Abstract: [Problem] Provided is a freeze-dried preparation containing high-purity PTH peptide and a method for the production thereof. Also provided is a test method for PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like. [Solution] In the present invention, the presence of PTH analogs produced during the manufacturing process of a freeze-dried preparation containing PTH peptide was confirmed. The production of these PTH analogs was also discovered to be markedly prevented or reduced by controlling exposure of the solution containing PTH peptide and the like to air environments within a pharmaceutical production facility.
    Type: Application
    Filed: May 31, 2012
    Publication date: March 27, 2014
    Applicant: ASAHI KASEI PHARMA CORPORATION
    Inventors: Fumihide Nishio, Takuji Maejima, Yoshiro Mitome
  • Publication number: 20140072531
    Abstract: A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol aqueous solution, the polymer microparticles prepared thereby, and use for drug delivery of the polymer microparticles.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 13, 2014
    Applicant: SK CHEMICALS CO., LTD.
    Inventors: Hong Kee KIM, Kyu Ho Lee, Joon-Gyo OH, Bong-Yong Lee